Women’s health, particularly in the area of infectious diseases, is critically important not only to women but also their partners and children. When health issues arise, it’s important to get reliable and fast answers for patients.
We offer highly sensitive, accurate, and easy to use diagnostic assays that enable laboratories to provide physicians and patients with accurate answers in a time-sensitive manner.
Our current assay portfolio includes:
Looking to design your own assay? We offer a diverse portfolio of primers for bacterial, fungal, protozoan, and viral pathogens. Learn more about MultiCode® Analyte Specific Reagents.***
Detect Streptococcus agalactiae, also known as Group B Streptococcus or GBS, from Lim broth enriched vaginal-rectal specimen swabs obtained from pregnant women using ARIES® Systems.
A real-time polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection and differentiation of HSV 1&2 DNA in cutaneous or mucocutaneous lesion specimens from symptomatic patients.
xMAP® MultiFLEX™ Zika RNA Assay is an FDA Emergency Use Authorized nucleic acid test for the qualitative detection and identification of the Zika virus in human serum, plasma, or urine (alongside matched serum or plasma) samples.
* For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.
** EUA – In Vitro Diagnostic Use Under Emergency Use Authorization. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization for use by authorized laboratories. This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
*** Analytical and performance characteristics are not established.